JOP20200078B1 - أجسام مضادة خاصة بـ cd47 وpd-l1 - Google Patents

أجسام مضادة خاصة بـ cd47 وpd-l1

Info

Publication number
JOP20200078B1
JOP20200078B1 JOJO/P/2020/0078A JOP20200078A JOP20200078B1 JO P20200078 B1 JOP20200078 B1 JO P20200078B1 JO P20200078 A JOP20200078 A JO P20200078A JO P20200078 B1 JOP20200078 B1 JO P20200078B1
Authority
JO
Jordan
Prior art keywords
antibodies
relates
specifically
antibodies specific
antigen
Prior art date
Application number
JOJO/P/2020/0078A
Other languages
English (en)
Inventor
Andrei Borisovich Ulitin
Valery Vladimirovich Solovyev
Dmitry Valentinovich Morozov
Timofey Aleksandrovich Nemankin
Kirill Vladimirovich Solovyev
Original Assignee
Biocad Joint Stock Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biocad Joint Stock Co filed Critical Biocad Joint Stock Co
Publication of JOP20200078A1 publication Critical patent/JOP20200078A1/ar
Application granted granted Critical
Publication of JOP20200078B1 publication Critical patent/JOP20200078B1/ar

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001129—Molecules with a "CD" designation not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/22—Immunoglobulins specific features characterized by taxonomic origin from camelids, e.g. camel, llama or dromedary
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

أجسام مضادة خاصة بـ CD47 وPD-L1 الملخص يتعلق الاختراع الحالي بمجال الهندسة الحيوية، وتحديداً بأجسام مضادة أو شظايا منها رابطة لمولد الضد، وباستخدامها. وبشكل أكثر تحديداً، يتعلق الاختراع الحالي بأجسام مضادة والتي ترتبط على وجه الخصوص بـ CD47 وPD-L1. يتعلق الاختراع أيضاً بحمض نووي والذي يقوم بترميز الجسم المضاد المحدد أو لشظية منه رابطة لمولد الضد، بناقل التعبير الوراثي، وبطريقة لإنتاج الجسم المضاد، وباستخدام الأجسام المضادة والتركيبات المذكورة سابقاً في علاج السرطان.
JOJO/P/2020/0078A 2017-10-03 2020-04-30 أجسام مضادة خاصة بـ cd47 وpd-l1 JOP20200078B1 (ar)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EA201791961A EA039662B1 (ru) 2017-10-03 2017-10-03 Антитела, специфичные к cd47 и pd-l1
PCT/EA2018/050001 WO2019068302A1 (ru) 2017-10-03 2018-10-03 Антитела, специфичные к cd47 и pd-l1

Publications (2)

Publication Number Publication Date
JOP20200078A1 JOP20200078A1 (ar) 2020-04-30
JOP20200078B1 true JOP20200078B1 (ar) 2024-04-17

Family

ID=65994976

Family Applications (1)

Application Number Title Priority Date Filing Date
JOJO/P/2020/0078A JOP20200078B1 (ar) 2017-10-03 2020-04-30 أجسام مضادة خاصة بـ cd47 وpd-l1

Country Status (21)

Country Link
US (1) US11840567B2 (ar)
EP (1) EP3693390A4 (ar)
JP (2) JP2020535839A (ar)
KR (1) KR102937863B1 (ar)
CN (1) CN111801352B (ar)
AR (1) AR113342A1 (ar)
AU (1) AU2018345458B2 (ar)
BR (1) BR112020006706A2 (ar)
CA (1) CA3078413A1 (ar)
CL (1) CL2020000919A1 (ar)
CO (1) CO2020004199A2 (ar)
EA (1) EA039662B1 (ar)
EC (1) ECSP20024555A (ar)
JO (1) JOP20200078B1 (ar)
MA (1) MA49599B1 (ar)
MX (1) MX2020004027A (ar)
PE (1) PE20210460A1 (ar)
PH (1) PH12020550214A1 (ar)
TW (1) TWI768129B (ar)
WO (1) WO2019068302A1 (ar)
ZA (1) ZA202002047B (ar)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11498977B2 (en) 2016-09-29 2022-11-15 Beijing Hanmi Pharmaceutical Co., Ltd. Heterodimeric immunoglobulin constructs and preparation methods thereof
CA3043652A1 (en) 2016-11-18 2018-05-24 Beijing Hanmi Pharmaceutical Co., Ltd. Anti-pd-1/anti-her2 natural antibody structural heterodimeric bispecific antibody and method of preparing the same
EA202091364A1 (ru) 2017-12-04 2020-10-13 Бейджин Ханми Фармасьютикал Ко., Лтд. Анти-pd-l1/анти-cd47 биспецифическое антитело с подобной природному антителу структурой и в форме гетеродимера и способ его получения
CN109970860A (zh) * 2017-12-27 2019-07-05 信达生物制药(苏州)有限公司 三链抗体、其制备方法及其用途
KR102839330B1 (ko) 2018-01-15 2025-07-30 난징 레전드 바이오테크 씨오., 엘티디. Pd-1에 대한 단일-도메인 항체 및 이의 변이체
WO2019153200A1 (zh) 2018-02-08 2019-08-15 北京韩美药品有限公司 抗pd-1/抗her2天然抗体结构样异源二聚体形式双特异抗体及其制备
EP3564263A1 (en) * 2018-05-03 2019-11-06 Universitätsklinikum Hamburg-Eppendorf Fusion proteins comprising a cell surface marker specific vhh
TW202104260A (zh) 2019-04-05 2021-02-01 美商西建公司 腫瘤選擇性結合ｃｄ４７之抗體之工程
CN113825774B (zh) * 2019-05-17 2024-07-30 南京金斯瑞生物科技有限公司 抗cd47/抗pd-l1多抗原结合蛋白及其使用方法
TWI761869B (zh) * 2019-06-25 2022-04-21 大陸商信達生物製藥（蘇州）有限公司 包含抗cd47/pd-l1雙特異性抗體的製劑及其製備方法和用途
US12358987B2 (en) * 2019-07-08 2025-07-15 Nanjing GenScript Biotech Co., Ltd. Anti-CD47/anti-PD-1 bispecific antibody, preparation method and use thereof
CN115052884B (zh) * 2019-09-27 2026-03-17 北京烁星生物医药科技有限公司 单特异性和多特异性抗体
CN112745392B (zh) * 2019-10-30 2022-07-01 上海洛启生物医药技术有限公司 抗pd-l1/cd47双特异性抗体及其用途
US11702474B2 (en) * 2019-12-17 2023-07-18 Pfizer Inc. Antibodies specific for CD47, PD-L1, and uses thereof
KR102939584B1 (ko) * 2020-02-12 2026-03-16 상하이 에스쿠겐 바이오테크놀로지 컴퍼니 리미티드 인간 cd47-표적화 단일-도메인 항체 및 그 사용
WO2022057939A1 (en) * 2020-09-21 2022-03-24 I-Mab Biopharma Co., Ltd. Pharmaceutical composition comprising cd47 antibody and pd-1/pd-l1 inhibitor
CA3191835A1 (en) * 2020-09-28 2022-03-31 Jiin-Tarng WANG Anti-cd47 antibodies and methods of use
EP4242232A4 (en) * 2020-11-06 2024-09-11 Bio-Thera Solutions, Ltd. BISPECIFIC ANTIBODY AND ITS USE
WO2022100694A1 (zh) * 2020-11-12 2022-05-19 迈威(上海)生物科技股份有限公司 抗体及其制备方法
JP7627349B2 (ja) * 2021-01-08 2025-02-05 北京韓美薬品有限公司 抗ｐｄ－ｌ１／抗ｃｄ４７天然抗体構造様ヘテロダイマー二重特異性抗体及びその製造方法
WO2022177393A1 (ko) * 2021-02-19 2022-08-25 (주)샤페론 Pd-l1에 대한 단일 도메인 항체 및 이의 용도
KR102836733B1 (ko) * 2021-02-19 2025-07-21 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 단일 도메인 항체 및 이의 용도
BR112023016713A2 (pt) * 2021-02-19 2023-10-31 Seoul Nat Univ R&Db Foundation Anticorpo ou um fragmento de ligação ao antígeno do mesmo, molécula de ácido nucleico, métodos para produzir um anticorpo ou um fragmento de ligação ao antígeno do mesmo e para detectar agrupamento de diferenciação 47 ou determinar uma quantidade de agrupamento de diferenciação 47 em uma amostra, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo
CA3219221A1 (en) * 2021-05-07 2022-11-10 Immuneoncia Therapeutics, Inc. Bispecific antibody specifically binding to cd47 and pd-l1
CN117858904A (zh) * 2021-06-21 2024-04-09 拜奥卡德联合股份公司 特异性结合cd47和pd-l1的分离的双特异性抗体
CN115702931A (zh) * 2021-08-06 2023-02-17 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在治疗疾病中的应用
WO2023051680A1 (zh) * 2021-09-30 2023-04-06 正大天晴药业集团股份有限公司 针对免疫检查点的双特异性抗体
EP4475886A4 (en) * 2022-02-09 2026-03-18 Exelixis Inc MULTI-SPECIFIC LIAISON AGENTS AND THEIR USES
KR20230163305A (ko) * 2022-05-19 2023-11-30 (주)샤페론 Pd-l1 및 cd47에 대한 이중특이적 인간화 단일 도메인 항체 및 이의 용도
KR20250044267A (ko) * 2022-07-28 2025-03-31 선전 엔듀어링 바이오테크 리미티드 Peg 기반 항-cd47/항-pd-l1 이중특이적 항체-약물 접합체
WO2024140702A1 (zh) * 2022-12-27 2024-07-04 广东菲鹏制药股份有限公司 一种双特异性结合分子及其应用
CN116063526B (zh) * 2022-12-31 2025-03-25 合肥天港免疫药物有限公司 抗pdl1的抗体及其用途
WO2024146539A1 (en) * 2023-01-04 2024-07-11 Wuxi Biologics (Shanghai) Co., Ltd. Bispecific antibodies against pd-l1 and cd47, method for preparing the same, and use thereof
WO2025133391A1 (en) * 2023-12-22 2025-06-26 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1
EP4574844A1 (en) * 2023-12-22 2025-06-25 Numab Therapeutics AG Multispecific antibodies having specificity for cd47 and pdl1
WO2025140478A1 (zh) * 2023-12-29 2025-07-03 百奥泰生物制药股份有限公司 抗pd-l1/cd47双特异抗体在联合用药中的应用

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4510245A (en) 1982-11-18 1985-04-09 Chiron Corporation Adenovirus promoter system
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4740461A (en) 1983-12-27 1988-04-26 Genetics Institute, Inc. Vectors and methods for transformation of eucaryotic cells
US5168062A (en) 1985-01-30 1992-12-01 University Of Iowa Research Foundation Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4968615A (en) 1985-12-18 1990-11-06 Ciba-Geigy Corporation Deoxyribonucleic acid segment from a virus
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4959455A (en) 1986-07-14 1990-09-25 Genetics Institute, Inc. Primate hematopoietic growth factors IL-3 and pharmaceutical compositions
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US4912040A (en) 1986-11-14 1990-03-27 Genetics Institute, Inc. Eucaryotic expression system
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
EP0479909B1 (en) 1989-06-29 1996-10-30 Medarex, Inc. Bispecific reagents for aids therapy
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
ATE204902T1 (de) 1990-06-29 2001-09-15 Large Scale Biology Corp Melaninproduktion durch transformierte mikroorganismen
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
ATE255131T1 (de) 1991-06-14 2003-12-15 Genentech Inc Humanisierter heregulin antikörper
FI941572L (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä
WO1993008829A1 (en) 1991-11-04 1993-05-13 The Regents Of The University Of California Compositions that mediate killing of hiv-infected cells
WO1993016185A2 (en) 1992-02-06 1993-08-19 Creative Biomolecules, Inc. Biosynthetic binding protein for cancer marker
EP0656064B1 (en) 1992-08-17 1997-03-05 Genentech, Inc. Bispecific immunoadhesins
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
CA2226962A1 (en) 1998-02-16 1999-08-16 Marie Sarfati Use of binding agents to cd47 and its ligands in the treatment or the prophylaxis of various inflammatory, autoimmune and allergic diseases and in the treatment of graft rejection
PT1210428E (pt) 1999-08-23 2015-07-21 Genetics Inst Llc Pd-1, um recetor para b7-4 e suas utilizações
US6517529B1 (en) 1999-11-24 2003-02-11 Radius International Limited Partnership Hemodialysis catheter
CN1220026C (zh) 2000-08-18 2005-09-21 林德股份公司 用于制造空气分离设备的方法
US7794710B2 (en) 2001-04-20 2010-09-14 Mayo Foundation For Medical Education And Research Methods of enhancing T cell responsiveness
CA2612241C (en) 2005-07-01 2018-11-06 Medarex, Inc. Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
US8168757B2 (en) * 2008-03-12 2012-05-01 Merck Sharp & Dohme Corp. PD-1 binding proteins
PL2342226T3 (pl) 2008-09-26 2017-01-31 Dana-Farber Cancer Institute, Inc. Ludzkie przeciwciała anty-PD-1, PD-L1 i PD-L2 oraz ich zastosowania
EP4209510B1 (en) 2008-12-09 2024-01-31 F. Hoffmann-La Roche AG Anti-pd-l1 antibodies and their use to enhance t-cell function
NO2504364T3 (ar) 2009-11-24 2018-01-06
EP4349868A3 (en) 2010-05-14 2024-08-28 The Board of Trustees of the Leland Stanford Junior University Humanized and chimeric monoclonal antibodies to cd47
EA034778B1 (ru) 2012-02-06 2020-03-19 Инхибркс, Инк. Антитела к cd47 и способы их применения
EP4706769A2 (en) 2012-12-03 2026-03-11 NovImmune SA Anti-cd47 antibodies and methods of use thereof
RU2015122228A (ru) 2012-12-12 2017-01-19 Васкулокс Инк. Терапевтические антитела к CD47
GB201300706D0 (en) 2013-01-15 2013-02-27 Cancer Rec Tech Ltd Antibody
JP2016507555A (ja) 2013-02-06 2016-03-10 インヒブルクス エルピー 血小板非減少性かつ赤血球非減少性ｃｄ４７抗体及びその使用方法
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
WO2016061142A1 (en) * 2014-10-14 2016-04-21 Novartis Ag Antibody molecules to pd-l1 and uses thereof
HK1257309A1 (zh) 2015-09-21 2019-10-18 Erasmus University Medical Center 抗-cd47抗体及使用方法
RU2665790C1 (ru) * 2017-04-17 2018-09-04 Закрытое Акционерное Общество "Биокад" Моноклональное антитело к pd-l1

Also Published As

Publication number Publication date
EA039662B1 (ru) 2022-02-24
PH12020550214A1 (en) 2021-02-15
NZ763865A (en) 2025-05-30
TW201922781A (zh) 2019-06-16
ZA202002047B (en) 2022-08-31
RU2020115122A3 (ar) 2021-10-29
CA3078413A1 (en) 2019-04-11
CO2020004199A2 (es) 2020-04-24
MX2020004027A (es) 2020-08-13
CL2020000919A1 (es) 2020-10-16
BR112020006706A2 (pt) 2020-10-06
US11840567B2 (en) 2023-12-12
CN111801352B (zh) 2025-01-14
EP3693390A4 (en) 2021-11-03
MA49599A1 (fr) 2021-01-29
RU2020115122A (ru) 2021-10-29
TWI768129B (zh) 2022-06-21
CN111801352A (zh) 2020-10-20
EP3693390A1 (en) 2020-08-12
US20200270345A1 (en) 2020-08-27
JP7676474B2 (ja) 2025-05-14
AU2018345458B2 (en) 2025-12-04
AU2018345458A1 (en) 2020-05-14
AU2018345458A2 (en) 2020-05-21
PE20210460A1 (es) 2021-03-08
JP2020535839A (ja) 2020-12-10
EA201791961A1 (ru) 2019-04-30
AR113342A1 (es) 2020-04-22
JOP20200078A1 (ar) 2020-04-30
KR102937863B1 (ko) 2026-03-12
ECSP20024555A (es) 2020-06-30
JP2023130455A (ja) 2023-09-20
MA49599B1 (fr) 2023-05-31
WO2019068302A1 (ru) 2019-04-11
KR20200058542A (ko) 2020-05-27

Similar Documents

Publication Publication Date Title
JOP20200078A1 (ar) أجسام مضادة خاصة بـ cd47 وpd-l1
ZA202311412B (en) Anti-phf-tau antibodies and uses thereof
PH12017500890A1 (en) Antibody drug conjugates
PH12019502298A1 (en) Monoclonal antibody to pd-l1
EP4039710A3 (en) Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
MX2022014463A (es) Construcciones de union a antigeno para moleculas diana.
MX384418B (es) Constructo de anticuerpo de cadena individual biespecífico con distribución mejorada de tejido.
EA201891709A1 (ru) Антигенсвязывающие белки, связывающие pd-l1
PE20180480A1 (es) Anticuerpos de factor xi y metodos de uso
PH12016501212B1 (en) Human anti-il-33 neutralizing monoclonal antibody
JO3788B1 (ar) تراكيب جسم مضاد لـ egfrviii وcd3
MX2024009271A (es) Constructos de anticuerpos de acidos nucleicos optimizados.
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
PH12021550521A1 (en) Antibodies that potently neutralize rabies virus and other lyssaviruses and uses thereof
EA201991845A1 (ru) Фармацевтические комбинации, содержащие антитело к ly75
TW201613971A (en) Anti-epidermal growth factor receptor (EGFR) antibodies
JOP20210286A1 (ar) جسم مضاد أحادي النسيلة يرتبط نوعياً مع gitr
CY1122728T1 (el) Αντισωματα εναντι hpa-1a
PH12020550218A1 (en) MONOCLONAL ANTIBODY TO IL-5Ra
MX2020003806A (es) Anticuerpos monoclonales de adn que se dirigen a ctla-4 para el tratamiento y prevención del cáncer.
UY37915A (es) Anticuerpos específicos para cd47 y pd-l1
EA202090449A1 (ru) Связывающие агенты, связывающие pd-l1 и cd137, и их применение